gray market glp 1 Glucagon-like peptide-1 (GLP-1) injectable medications have shown a lot of promise for managing chronic conditions like diabetes and obesity. But their popularity and price has spurred many lookalikes that are not GLP-1s Over 80% of #GLP1 medication

In collaboration with Steno Diabetes Center, we also plan to analyze blood samples from patients who have either received GLP-1-based treatment or undergone bariatric surgery, to see whether one of these approaches has a stronger effect on inflammation more broadly

Therefore, fully understanding the pathogenesis of OA would be helpful in exploring novel therapies

Here's why that's BS: By the time glucose tests show abnormalities, you've likely had insulin resistance for years

Conclusion and Future Directions With the recent increase in GLP-1 RA use, it is essential to explore and understand the impact of these medications on the performance of gastrointestinal procedures such as EGD and colonoscopy